Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

The history of breakthrough weight loss medicines is riddled with tragic results. Based on the histories of phen-fen and ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss ... 2021 to December 2023, of which 58.9% were female. The overall prevalence of discontinuation of GLP-1 ...

Novo Nordisk (NYSE:NVO)'s new weight loss drug CagriSema missed the company's ... which has been available since 2021. Novo Nordisk then introduced CagriSema that is basically an upgrade version ...

Data from the National Health and Nutrition Examination study show that between 2021-2023 ... And what about the new weight loss drugs? The Kaiser Family Foundation reported in its spring 2024 ...

Notably, the dip in Novo Nordisk’s stock has been attributed to subpar clinical trial results for its new weight-loss drug CagriSema along with patent concerns. That said, over the last three ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

They investigated 12 medications — three that the US Food and Drug Administration (FDA) has approved for weight loss and nine it hasn’t. The drugs mimic GLP-1, a hormone the body naturally ...

Novo Nordisk (NYSE:NVO)'s new weight loss drug CagriSema missed the company's target of reducing ... which has been available since 2021. Novo Nordisk then introduced CagriSema that is basically an ...